Page last updated: 2024-08-21

nsc 65346 and alvocidib

nsc 65346 has been researched along with alvocidib in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Allen, JE; Aqui, N; Dicker, DT; Dolloff, NG; El-Deiry, WS; Malysz, J; Talamo, G; Vogl, D	1

Other Studies

1 other study(ies) available for nsc 65346 and alvocidib

Article	Year
Sangivamycin-like molecule 6 exhibits potent anti-multiple myeloma activity through inhibition of cyclin-dependent kinase-9. Molecular cancer therapeutics, 2012, Volume: 11, Issue:11 Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cell Death; Cell Line, Tumor; Cyclin-Dependent Kinase 9; Drug Screening Assays, Antitumor; Flavonoids; Humans; Mice; Multiple Myeloma; Oncogenes; Piperidines; Protein Kinase Inhibitors; Pyrazines; Pyrimidine Nucleosides; Translocation, Genetic; Treatment Outcome; Tubercidin	2012

Article

Year

Sangivamycin-like molecule 6 exhibits potent anti-multiple myeloma activity through inhibition of cyclin-dependent kinase-9.

Molecular cancer therapeutics, 2012, Volume: 11, Issue:11

Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cell Death; Cell Line, Tumor; Cyclin-Dependent Kinase 9; Drug Screening Assays, Antitumor; Flavonoids; Humans; Mice; Multiple Myeloma; Oncogenes; Piperidines; Protein Kinase Inhibitors; Pyrazines; Pyrimidine Nucleosides; Translocation, Genetic; Treatment Outcome; Tubercidin

2012